Sarepta Therapeutics, Inc.’s ongoing EMBARK trial to confirm the clinical benefit of its Duchenne muscular dystrophy gene therapy Elevidys also will serve as the foundation for a substantial label expansion expected in 2024.
Elevidys (delandistrogene moxeparvovec-rokl) received an accelerated approval from the US Food and Drug Administration on 22 June for four- and...






